Significance of Fibulin-3 Expression in Bladder Cancer: a Tissue Microarray-based Immunohistochemical Study

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2022 Apr 27

PMID 35473807

Authors

Ali Al Khader

Abdul Fattah S Fararjeh

Ezidin G Kaddumi

Mohamad Al-Saghbini

Affiliations

Soon will be listed here.

Abstract

Background: Predicting the behavior of bladder cancer by easy noninvasive methods and with less cost is needed. Fibulin-3 (EFEMP1), a glycoprotein of the extracellular matrix that is encoded by the gene EFEMP1, has been nominated as one of the potential mediators of muscle invasion in bladder cancer.

Methods: In this tissue microarray-based immunohistochemical study, fibulin-3 level of expression was evaluated using a semiquantitative scoring system and was correlated with patient's age and sex and tumor grade and stage.

Results: A total of 160 urothelial carcinoma cases were analyzed. The age of the patients ranged from 25 to 91 years (mean, 60.15; SD, 11.60). Fibulin-3 was significantly associated with muscle invasion and overall tumor stage (p = 0.033 and 0.02, respectively). Fibulin-3 expression was nonsignificantly associated with tumor grade (p = 0.092) CONCLUSIONS: We found that the expression of fibulin-3 is significantly associated with muscle invasion in urinary bladder urothelial carcinoma. However, the prognostic role of fibulin-3 needs further investigations.

Citing Articles

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.

Harsanyi S, Kianickova K, Katrlik J, Danisovic L, Ziaran S J Cancer Res Clin Oncol. 2024; 150(2):96.

PMID: 38372785 PMC: 10876723. DOI: 10.1007/s00432-024-05623-7.

Unveiling the role of osteosarcoma-derived secretome in premetastatic lung remodelling.

Almeida S, Santos L, Sampaio-Ribeiro G, Ferreira H, Lima N, Caetano R J Exp Clin Cancer Res. 2023; 42(1):328.

PMID: 38031171 PMC: 10688015. DOI: 10.1186/s13046-023-02886-9.

References

Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B . Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 2008; 124(7):1727-35. DOI: 10.1002/ijc.24108. View

Almeida M, Costa V, Costa N, Ramalho-Carvalho J, Baptista T, Ribeiro F . Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med. 2014; 18(11):2287-97. PMC: 4224561. DOI: 10.1111/jcmm.12394. View

Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W . Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res. 2007; 13(15 Pt 1):4336-44. DOI: 10.1158/1078-0432.CCR-07-0015. View

Wang X, Zhu L, Wu J, Zhao Y . The expression of Fibulin-3 in ovarian cancer and its relationship with prognosis. Transl Cancer Res. 2022; 9(9):5173-5181. PMC: 8799201. DOI: 10.21037/tcr-20-984. View

Mao H, Liu S, Kong G, Xu Y, Xu Y, Sun G . FBLN3 inhibited the invasion and metastasis of colorectal cancer through the AKT/mTOR pathway. Neoplasma. 2019; 66(3):336-342. DOI: 10.4149/neo_2018_180703N441. View

Hu J, Duan B, Jiang W, Fu S, Gao H, Lu L . Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B). Cancer Med. 2019; 8(6):3152-3166. PMC: 6558597. DOI: 10.1002/cam4.2144. View

Chen T, Chan T, Li W, Li C, Ke H, Wei Y . Utility of EFEMP1 in the Prediction of Oncologic Outcomes of Urothelial Carcinoma. Genes (Basel). 2021; 12(6). PMC: 8226762. DOI: 10.3390/genes12060872. View

Jiang Z, Shen W, Ying S, Gao Z, He X, Chen R . Overexpression of fibulin-3 in tumor tissue predicts poor survival of malignant mesothelioma patients from hand-spinning asbestos exposed area in eastern China. Sci Rep. 2020; 10(1):20373. PMC: 7683741. DOI: 10.1038/s41598-020-77412-4. View

Shi H, Yu J, Yu J, Feng Z, Zhang C, Li G . Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles. World J Surg Oncol. 2017; 15(1):147. PMC: 5543742. DOI: 10.1186/s12957-017-1201-9. View

10.

Dong F, Shen Y, Xu T, Wang X, Gao F, Zhong S . Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis. World J Surg Oncol. 2018; 16(1):61. PMC: 5863379. DOI: 10.1186/s12957-018-1358-x. View

11.

Han A, Veeneman B, El-Sawy L, Day K, Day M, Tomlins S . Fibulin-3 promotes muscle-invasive bladder cancer. Oncogene. 2017; 36(37):5243-5251. DOI: 10.1038/onc.2017.149. View

12.

Lecka-Czernik B, Lumpkin Jr C, Goldstein S . An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis. Mol Cell Biol. 1995; 15(1):120-8. PMC: 231918. DOI: 10.1128/MCB.15.1.120. View

13.

Hu B, Nandhu M, Sim H, Agudelo-Garcia P, Saldivar J, Dolan C . Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res. 2012; 72(15):3873-85. PMC: 3896095. DOI: 10.1158/0008-5472.CAN-12-1060. View

14.

Han Y, Liu X, Ye H, Tian Y, Ji Z . Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis. World J Surg Oncol. 2020; 18(1):310. PMC: 7694425. DOI: 10.1186/s12957-020-02084-3. View

15.

Wang Z, Cao C, Huang L, Ke Z, Luo C, Lin Z . EFEMP1 promotes the migration and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via NF-κB signaling pathway. Oncotarget. 2015; 6(16):14191-208. PMC: 4546460. DOI: 10.18632/oncotarget.3691. View

16.

Liu J, Zhang Z, Liu X, Zhang W, Meng L, Wang J . Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response. World J Surg Oncol. 2022; 20(1):47. PMC: 8867683. DOI: 10.1186/s12957-022-02514-4. View

17.

Lecka-Czernik B, Moerman E, Jones R, Goldstein S . Identification of gene sequences overexpressed in senescent and Werner syndrome human fibroblasts. Exp Gerontol. 1996; 31(1-2):159-74. DOI: 10.1016/0531-5565(95)02014-4. View

18.

Li W, Ye L, Chen Y, Chen P . P3H4 is correlated with clinicopathological features and prognosis in bladder cancer. World J Surg Oncol. 2018; 16(1):206. PMC: 6190559. DOI: 10.1186/s12957-018-1507-2. View

19.

Chan T, Wu W, Li W, Shiao M, Shiue Y, Li C . SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics. 2020; 10(25):11775-11793. PMC: 7546005. DOI: 10.7150/thno.51655. View

20.

Du J, Wang S, Yang Q, Chen Q, Yao X . p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J Surg Oncol. 2016; 14:137. PMC: 4851770. DOI: 10.1186/s12957-016-0890-9. View